查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585564

分叉病变市场：按类型、按应用划分 - 2025-2030 年全球预测

Bifurcation Lesions Market by Type (One-Stent, Two-Stent), Application (Coronary Vascular, Peripheral Vascular) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年分叉病变市值为32.3亿美元，预计到2024年将达到35.6亿美元，复合年增长率为10.63%，到2030年将达到65.6亿美元。

分叉病变是冠状动脉疾病的一种，当动脉粥状硬化斑块在血管分叉处或附近形成时就会发生。解决这些病变至关重要，因为它们很复杂，并且可能在经皮冠状动脉介入治疗 (PCI) 期间引起併发症。这些病变需要高度专业化的支架和介入措施，使其成为心血管治疗的重要组成部分。人口老化、心血管疾病盛行率增加以及支架留置技术的进步推动了分叉病变干预市场。关键的成长要素包括新一代药物释放型支架、分叉专用支架以及诊断影像技术的改进以优化治疗结果。最新的潜在机会在于生物可吸收支架的开发和诊断成像模式的改进，例如光同调断层扫瞄（OCT），以帮助准确的病变评估和设备定位。鼓励公司投资研发，以创新解决方案来解决这些具体方面。然而，市场面临严格的监管要求、高昂的手术成本以及需要熟练的心臟科医师进行复杂干预等挑战。限制包括支架内血栓症和血管再阻塞的可能性。技术创新的一个有前景的领域是开发专用的分叉设备和成像技术，这些设备和成像技术可以无缝整合到现有的导管实验室中，从而提高手术的成功率。科技公司和医疗保健提供者之间的合作可以带来设备创新和手术通讯协定的突破。市场参与企业需要保持敏捷并定期更新其产品，以跟上不断变化的监管标准和技术进步的步伐。提高介入性心臟病专家技能的培训计划也提供了市场扩张机会。儘管存在竞争，但对于那些能够驾驭监管环境并解决未满足的临床需求的公司来说，这个市场具有巨大的潜力。了解分叉病变的微妙性质并继续与医疗保健提供者进行对话可能是确定策略成长路径的关键。

主要市场统计
基准年[2023] 32.3亿美元
预测年份 [2024] 35.6亿美元
预测年份 [2030] 65.6亿美元
复合年增长率（%） 10.63%

市场动态：快速发展的分叉病变市场的关键市场洞察

供给和需求的动态交互作用正在改变分叉病变市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球冠状动脉疾病盛行率不断上升
    • 老年人口增加和与老龄化相关的疾病增加
    • 改善医疗基础设施以及对微创手术的偏好
  • 市场限制因素
    • 该行业缺乏熟练的专业人才
  • 市场机会
    • 持续研发引进新的处理技术
    • 涉及球囊和支架的临床试验迅速增加
  • 市场挑战
    • 严格的法规和标准

波特五力：驾驭分岔病变市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解分叉病变市场的外部影响

外部宏观环境因素对于塑造分叉病变市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解分叉病变市场的竞争状况

对分叉病变市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV定位矩阵分叉病变市场厂商绩效评估

FPNV定位矩阵是评估分叉病变市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了分叉病变市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对分叉病变市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球冠状动脉疾病盛行率增加
      • 老年人口增加和与老龄化相关的疾病
      • 改善医疗基础设施并优先考虑微创手术
    • 抑制因素
      • 该行业缺乏熟练的专业人才
    • 机会
      • 持续研发引进新的处理技术
      • 球囊和支架临床试验迅速增加
    • 任务
      • 严格的法规和标准
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章分叉病变市场：依类型

  • 一个支架
  • 2 个支架

第七章分叉病变市场：依应用分类

  • 冠状血管
  • 周围血管

第8章：美洲分叉病变市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太分叉病变市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章：欧洲/中东/非洲分叉病变市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Absolute-DSi
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Cook Group Incorporated
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Olympus Corporation
  • Stryker Corporation
  • Tecomet, Inc.
  • Terumo Corporation
  • Tryton Medical, Inc.
Product Code: MRR-BD6F81433E75

The Bifurcation Lesions Market was valued at USD 3.23 billion in 2023, expected to reach USD 3.56 billion in 2024, and is projected to grow at a CAGR of 10.63%, to USD 6.56 billion by 2030.

Bifurcation lesions, a type of coronary artery disease, occur when atherosclerotic plaques develop at or near a vessel branch. The need to address these lesions is critical due to their complexity and potential risk of procedural complications during percutaneous coronary interventions (PCI). These lesions require highly specialized stents or interventions, making them a pivotal component of cardiovascular treatment. The market for bifurcation lesion interventions is driven by an aging population, increasing prevalence of cardiovascular diseases, and advancements in stenting technologies. Key growth factors include the advent of new-generation drug-eluting stents, bifurcation-specific stents, and enhanced imaging techniques which optimize treatment outcomes. The latest potential opportunities lie in the development of bioresorbable scaffolds and improved imaging modalities such as optical coherence tomography (OCT) which aid in precise lesion assessment and device positioning. Companies are encouraged to invest in R&D to innovate solutions that address these specific aspects. However, the market faces challenges like stringent regulatory requirements, high procedural costs, and the need for skilled cardiologists to perform complex interventions. Limitations include potential stent thrombosis or restenosis. A promising area of innovation is the development of dedicated bifurcation devices and imaging technology that can seamlessly integrate into existing catheter labs, thus enhancing procedural success rates. Collaboration between technology firms and medical institutions could lead to breakthroughs in device innovation and procedural protocols. Market participants need to be agile, regularly updating their offerings to meet evolving regulatory standards and technological advancements. Training programs to improve the skills of interventional cardiologists also present market expansion opportunities. While competitive, the market holds significant promise for businesses that can navigate the regulatory landscape and address unmet clinical needs. Understanding the nuanced nature of bifurcation lesions and continuing dialogue with healthcare providers will be key in identifying strategic growth avenues.

KEY MARKET STATISTICS
Base Year [2023] USD 3.23 billion
Estimated Year [2024] USD 3.56 billion
Forecast Year [2030] USD 6.56 billion
CAGR (%) 10.63%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bifurcation Lesions Market

The Bifurcation Lesions Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of coronary artery diseases globally
    • Rising elderly population and the medical ailments associated with age
    • Improving healthcare infrastructure coupled with preference for minimally invasive surgeries
  • Market Restraints
    • Lack of skilled professional in the industry
  • Market Opportunities
    • Ongoing research and development toward introduction novel treatment techniques
    • Surge in the number of clinical trials on balloons and stents
  • Market Challenges
    • Stringent regulations and standards

Porter's Five Forces: A Strategic Tool for Navigating the Bifurcation Lesions Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bifurcation Lesions Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bifurcation Lesions Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bifurcation Lesions Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bifurcation Lesions Market

A detailed market share analysis in the Bifurcation Lesions Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bifurcation Lesions Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bifurcation Lesions Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bifurcation Lesions Market

A strategic analysis of the Bifurcation Lesions Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bifurcation Lesions Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Absolute-DSi, B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cardinal Health Inc., Cook Group Incorporated, Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Medtronic PLC, MicroPort Scientific Corporation, Olympus Corporation, Stryker Corporation, Tecomet, Inc., Terumo Corporation, and Tryton Medical, Inc..

Market Segmentation & Coverage

This research report categorizes the Bifurcation Lesions Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across One-Stent and Two-Stent.
  • Based on Application, market is studied across Coronary Vascular and Peripheral Vascular.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of coronary artery diseases globally
      • 5.1.1.2. Rising elderly population and the medical ailments associated with age
      • 5.1.1.3. Improving healthcare infrastructure coupled with preference for minimally invasive surgeries
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled professional in the industry
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development toward introduction novel treatment techniques
      • 5.1.3.2. Surge in the number of clinical trials on balloons and stents
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and standards
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bifurcation Lesions Market, by Type

  • 6.1. Introduction
  • 6.2. One-Stent
  • 6.3. Two-Stent

7. Bifurcation Lesions Market, by Application

  • 7.1. Introduction
  • 7.2. Coronary Vascular
  • 7.3. Peripheral Vascular

8. Americas Bifurcation Lesions Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Bifurcation Lesions Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Bifurcation Lesions Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Absolute-DSi
  • 3. B. Braun SE
  • 4. Becton, Dickinson and Company
  • 5. BIOTRONIK SE & Co. KG
  • 6. Boston Scientific Corporation
  • 7. Cardinal Health Inc.
  • 8. Cook Group Incorporated
  • 9. Johnson & Johnson Services, Inc.
  • 10. Koninklijke Philips N.V.
  • 11. Medtronic PLC
  • 12. MicroPort Scientific Corporation
  • 13. Olympus Corporation
  • 14. Stryker Corporation
  • 15. Tecomet, Inc.
  • 16. Terumo Corporation
  • 17. Tryton Medical, Inc.

LIST OF FIGURES

  • FIGURE 1. BIFURCATION LESIONS MARKET RESEARCH PROCESS
  • FIGURE 2. BIFURCATION LESIONS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIFURCATION LESIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BIFURCATION LESIONS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BIFURCATION LESIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIFURCATION LESIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIFURCATION LESIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIFURCATION LESIONS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY ONE-STENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY TWO-STENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY CORONARY VASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. BIFURCATION LESIONS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. BIFURCATION LESIONS MARKET, FPNV POSITIONING MATRIX, 2023